Related keylists
Luye Pharma Group Ltd (Luye Pharma), a subsidiary of Luye Life Sciences Group Ltd, is a drug development company. It discovers, manufactures and commercializes novel formulations, generic drugs and pharmaceutical products. The company offers its products in the form of tablets, formulations for injections, capsules, gels, anti-psychotic medicines and modified-release dosages in the therapeutic areas of oncology, cardiovascular, orthopedics, hepatology, gastroenterology, gynecology, diabetes and central nervous system (CNS). Luye Pharma operates its research and development and manufacturing facilities in the US and China and, among others. Luye Pharma is headquartered in Yantai, Shandong, China.
Headquarters
China
Address
Suite 3207, Champion Tower, 3 Garden Road, Central, Yantai, Shandong , 264003
Website
www.luye.cn/lvye
Telephone
86 535 6717618
No of Employees
5,005
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2186 (HKG)
Revenue (2022)
$868.6M
2.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-11.9%
(2022 vs 2021)
Market Cap*
$1.3B
Net Profit Margin (2022)
XYZ
-14.2%
(2022 vs 2021)
* As of and is in US$
Luye Pharma Group Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Oncology: | Seroquel XR |
| Tiandida (Amifostine for Injection) | BeiXi |
| Tiandixin (Lentinan for Injection) | Lutingnuo |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company entered into a partnership with Joincare Pharmaceutical Group Industry Co. Ltd. to develop and commercialize BA2101 in the Chinese Mainland to treat respiratory diseases such as asthma and COPD. |
| 2023 | Regulatory Approval | In December, the company secured approval from the Pharmacy and Poisons Board of the Hong Kong Special Administrative Region for ZEPZELCA to treat adult patients with metastatic small-cell lung cancer. |
| 2023 | Regulatory Approval | In July, the company and BeiGene announced that Luye Pharma's innovative formulation, Goserelin Microspheres for Injection (Baituowei) was approved by China’s National Medical Products Administration (NMPA). |
Competitor Comparison
| Key Parameters | Luye Pharma Group Ltd | Pacific Shuanglin Bio-pharmacy Co Ltd | Jiangsu Lianhuan Pharmaceutical Co Ltd | Sihuan Pharmaceutical Holdings Group Ltd | AccuBioTech Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Yantai | Zhanjiang | Yangzhou | Beijing | Beijing |
| State/Province | Shandong | Guangdong | Jiangsu | Beijing | Beijing |
| No. of Employees | 5,005 | 2,093 | 1,296 | 3,241 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Liu Dian Bo | Chief Executive Officer; Chairman | Executive Board | 2003 | 57 |
| Yang Rong Bing | Vice Chairman | Executive Board | 2007 | 57 |
| Yuan Hui Xian | Director | Executive Board | 2003 | 64 |
| Zhu Yuan Yuan | Director | Executive Board | - | 42 |
| Liu Yuan Chong | Chief Financial Officer | Senior Management | - | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward